Disease relevance of La Crosse Virus

• Here we demonstrate that MxA binds to the nucleocapsid protein of La Crosse virus (LACV) and colocalizes with the viral protein in cytoplasmic complexes [1].
• It exhibited a marked reduction in its ability to replicate in striated muscle and to produce viremia; however, after intracerebral injection V22 virus replicated almost as rapidly in brain as its parent, La Crosse virus [2].
• The L protein of La Crosse virus was observed to migrate ahead of its Tahyna virus counterpart when electrophoresed through a 5% acrylamide resolving gel [3].
• We have developed a system for the preparation of La Crosse virus (LAC) and Hantaan virus (HTN) pseudotypes using a murine leukemia virus vector [4].

High impact information on La Crosse Virus

• A membrane glycoprotein that accumulates intracellularly: cellular processing of the large glycoprotein of LaCrosse virus [5].
• La Crosse virus nonstructural protein NSs counteracts the effects of short interfering RNA [6].
• These results indicate that (i) the G1 protein by itself can induce an immune response sufficient for protection from a lethal challenge with La Crosse virus, (ii) a neutralizing humoral response correlates with protection, and (iii) the context in which G1 is presented affects its immunogenicity [7].
• Pretreatment of the cultures with actinomycin D does not affect the ability of La Crosse virus infection to induce mRNA instability, and examination of the rRNAs shows no evidence of specific degradation due to activation of the interferon-associated latent RNase [8].
• Mechanism of La Crosse virus inhibition by ribavirin [9].

Chemical compound and disease context of La Crosse Virus

• Inhibition of La Crosse virus replication by monensin, monovalent ionophore [10].
• Production of hemagglutinating of La Crosse virus by polyethylene glycol precipitation [11].
• LaCrosse virus infection of mammalian BHK cells is highly cytopathic, whereas that of mosquito C6/36 cells is asymptomatic and persistent [12].

Biological context of La Crosse Virus

• Monoclonal antibodies specific for eight antigenic sites on the G1 glycoprotein of La Crosse virus were studied in a kinetics of neutralization assay [13].
• Competitive binding assays with monoclonal antibodies have been used to show that there are a minimum of three nonoverlapping antigenic sites on the G1 glycoprotein of La Crosse virus [14].

Anatomical context of La Crosse Virus

• The La Crosse virus G1 glycoprotein plays a critical role in virus binding to susceptible cells and in the subsequent fusion of viral and cellular membranes [15].

Gene context of La Crosse Virus

• The G2 envelope glycoprotein of La Crosse virus (LAC) was proposed by Ludwig et al. to be a determinant for virus attachment to mosquito midgut cells [16].
• Surveillance of container-inhabiting mosquitoes was conducted from June 17 through November 9, 1998, at 2 1997 La Crosse virus (LAC) human case sites (Knox and Cocke counties, Tennessee) [17].

Analytical, diagnostic and therapeutic context of La Crosse Virus

• Mammalian and arthropod cell cultures were used to assess the neutralizing activity of six monoclonal antibodies specific for the G1 glycoprotein of La Crosse virus [18].

References